Chronic Hand Eczema (CHE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Chronic Hand Eczema (CHE) Market Outlook

Thelansis’s “Chronic Hand Eczema (CHE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Hand Eczema treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Hand Eczema (CHE) Overview

Chronic Hand Eczema (CHE) encompasses either a persistent, recurring manifestation of hand eczema (HE) enduring beyond three months or HE resistant to conventional treatment with emollients and topical corticosteroids, characterized by symptoms recurring twice yearly despite intervention. Clinical manifestations of CHE include typical eczema features localized to the hands and fingers, such as dryness, redness, swelling, thickening of the skin, flaking, hardening, roughness, blistering, cracking, itching, and discomfort. Hand eczema can be broadly classified into three primary etiological categories: irritant contact dermatitis (ICD), allergic contact dermatitis (ACD), and atopic hand eczema, constituting more than half of all cases. Eczema and dermatitis are used interchangeably to denote a specific inflammatory condition affecting the epidermis and dermis of the skin. Acute and subacute HE denotes eczematous changes confined to the hands, persisting for less than three months and occurring no more than once annually. In the acute phase, vesicles are commonly present, though not universally, in irritant HE. Erythema, indicative of inflammation, is prominent in acute HE, alongside swelling. Burning and itching sensations are subjectively reported in most instances. Chronic HE refers to an ongoing eczematous process exceeding three months in duration or recurring at least twice annually. Scaling and fissuring are prevalent features, with hyperkeratosis observed in chronic irritant and allergic HE, as well as in endogenous hyperkeratotic HE and other persistent cases. There exists a significant therapeutic gap for effectively managing CHE long-term, particularly in moderate-to-severe instances, with no FDA-approved treatments currently available for chronic hand eczema. Delgocitinib, a JAK-inhibitor cream developed by Leo Pharma, has obtained fast-track designation from the U.S. Food and Drug Administration (FDA) for chronic hand eczema, offering potential promise in addressing this unmet need.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: